- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00222664
Qidong Hepatitis B Intervention Study
September 13, 2005 updated by: University of Oxford
During 1983-1990 in the Jiangsu province of China, 80,000 infants were randomised by area of birth between control, standard Hepatitis B vaccination (at 0, 1 and 6 months of age) and standard vaccination plus a booster dose at about 2 to 3 years of age.
The aim is to prevent establishment of chronic HBV infection in early childhood, hence to prevent the morbidity of chronic hepatitis B in young adolescents and the incidence/mortality several decades later from liver cancer and other HBV related chronic liver diseases.
Long-term follow-up through central registries will determine the impact of vaccination on liver cancer incidence and mortality.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
80000
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Cancer Institute, Chinese Academy of Medical Sciences
-
-
Jiangsu
-
Qidong, Jiangsu, China
- Qidong Liver Cancer Institute
-
-
-
-
-
Oxford, United Kingdom, OX3 7LF
- Clinical Trial Service Unit and Epidemiological Studies Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
all infants born in Qidong between September 1983 and November 1990
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Zongtang Sun, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Study Director: Richard Peto, Msc, University of Oxford
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1983
Study Completion
December 1, 2004
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 22, 2005
Study Record Updates
Last Update Posted (Estimate)
September 22, 2005
Last Update Submitted That Met QC Criteria
September 13, 2005
Last Verified
August 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Liver Diseases
- Hepatitis B
- Hepatitis
- Hepatitis A
- Liver Neoplasms
Other Study ID Numbers
- Qidong-HBV-Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
Clinical Trials on Hep-V Vax
-
Chonnam National University HospitalUnknownMultiple MyelomaKorea, Republic of
-
University of PennsylvaniaPhiladelphia Department of Public HealthCompleted
-
Entos Pharmaceuticals Inc.Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma... and other collaboratorsCompletedSARS-CoV-2Burkina Faso, Canada, Senegal, South Africa
-
Loyola UniversityColumbia UniversityRecruitingInflammation | Stress | RacismUnited States
-
Inmunotek S.L.CompletedImmune System DiseasesSpain
-
IlDong Pharmaceutical Co LtdCompleted
-
Baiya Phytopharm Co., Ltd.National Vaccine Institute, ThailandActive, not recruiting
-
Uppsala UniversityKarolinska Institutet; Cyto Pulse Sciences, Inc.Completed
-
Istanbul University - Cerrahpasa (IUC)CompletedInvestigation of the Effectiveness of Environmental Enrichment-Based Intervention in Preterm InfantsDevelopment, Infant | Therapy | Preterm | MotorTurkey
-
University of Wisconsin, MadisonNational Center for Complementary and Integrative Health (NCCIH)CompletedMental Health | HealthUnited States